Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Federal Trade Commission
Cantor Fitzgerald
Farmers Insurance
Cerilliant
Mallinckrodt
Moodys
Daiichi Sankyo
AstraZeneca

Generated: June 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203150

« Back to Dashboard

NDA 203150 describes QUETIAPINE FUMARATE, which is a drug marketed by Accord Hlthcare, Anchen Pharms, Aurobindo Pharma Ltd, Intellipharmaceutics, Lupin Ltd, Macleods Pharms Ltd, Novast Labs Ltd, Par Pharm, Pharmadax Inc, Sciegen Pharms Inc, Actavis Grp Ptc, Alembic Pharms Ltd, Alkem Labs Ltd, Apotex Inc, Dr Reddys Labs Ltd, Jubilant Generics, Mylan Pharms Inc, Sandoz, Sun Pharma Global, Teva Pharms, Torrent Pharms Ltd, Unichem Labs Ltd, and West-ward Pharms Int, and is included in twenty-nine NDAs. It is available from fifty-one suppliers. Additional details are available on the QUETIAPINE FUMARATE profile page.

The generic ingredient in QUETIAPINE FUMARATE is quetiapine fumarate. There are fifty-two drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the quetiapine fumarate profile page.
Summary for 203150
Tradename:QUETIAPINE FUMARATE
Applicant:Jubilant Generics
Ingredient:quetiapine fumarate
Patents:0
Therapeutic Class:Antipsychotics
Bipolar Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 203150
Medical Subject Heading (MeSH) Categories for 203150
Suppliers and Packaging for NDA: 203150
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
QUETIAPINE FUMARATE quetiapine fumarate TABLET;ORAL 203150 ANDA Jubilant Cadista Pharmaceuticals Inc. 59746-348 N 59746-348-01
QUETIAPINE FUMARATE quetiapine fumarate TABLET;ORAL 203150 ANDA Jubilant Cadista Pharmaceuticals Inc. 59746-348 N 59746-348-03

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 25MG BASE
Approval Date:Nov 26, 2013TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Fish and Richardson
Teva
Dow
Accenture
Boehringer Ingelheim
Cerilliant
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.